Literature DB >> 24641721

Renal replacement therapy in Brunei Darussalam: comparing standards with international renal registries.

Jackson Tan1.   

Abstract

BACKGROUND AND AIM: Brunei Darussalam is a small South East Asian country with a high prevalence and incidence of end stage kidney disease (ESRD). This study aims to compare key performance indicators recorded in the Brunei Dialysis and Transplant Registry and department records against international practice. Registries from the USA (USRDS), UK (UK Renal Registry), Australasia (ANZDATA), Europe (ERA-EDTA Registry) and Malaysia (MDTR) were used for comparisons. METHODS AND
RESULTS: Haemodialysis (83%) and renal transplantation (6%) were the most and least favoured modality of renal replacement therapy in Brunei. Diabetes mellitus as a cause of ESRD (57%) was high in Brunei but on par with other South East Asian countries. Dialysis death rates (11%) and living-related transplant survival rates (5 year graft and patient survival 91% and 96% respectively) were favourable compared with other registries. Anaemia and mineral bone disease management were similar to Malaysia but slightly inferior to the others, but generally in keeping with KDOQI and KDIGO targets. Haemodialysis adequacy (48% achieving urea reduction ratio of >65%) was relatively poorer due to poor dialysis flow rates and low fistula usage (71%). Peritoneal dialysis peritonitis (24.5 patient-month/episode) and adequacy (78% achieving kt/v of 1.7) were in keeping with ISPD targets and international registries' results.
CONCLUSION: Brunei has achieved reasonable and commendable standards in many areas pertaining to the renal services. This report has identified several key areas for developments but this is to be expected for a service making its first foray into international benchmarked practice.
© 2014 Asian Pacific Society of Nephrology.

Entities:  

Keywords:  Brunei; dialysis; end stage renal disease; registry; transplant

Mesh:

Year:  2014        PMID: 24641721     DOI: 10.1111/nep.12228

Source DB:  PubMed          Journal:  Nephrology (Carlton)        ISSN: 1320-5358            Impact factor:   2.506


  5 in total

1.  Outcomes of Renal Transplantation in Brunei Darussalam over a Twenty-Year Period (1993-2012).

Authors:  Jackson Tan; Muhammad Abdul Mabood Khalil; Si Yen Tan; Muhammad Khalil; Dalinatul Ahmed; Shaukat Zinna; William Chong
Journal:  J Transplant       Date:  2014-11-12

Review 2.  A Comprehensive Analysis of the Current Status and Unmet Needs in Kidney Transplantation in Southeast Asia.

Authors:  Chitranon Chan-On; Minnie M Sarwal
Journal:  Front Med (Lausanne)       Date:  2017-06-23

3.  The Living-Related Kidney Transplant Program in Brunei Darussalam: Lessons Learnt from a Nascent National Program in a Small, Muslim, and Asian Country.

Authors:  Jackson Tan; Muhammad Abdul Mabood Khalil; Dalinatul Ahmed; Jayakrishnan Pisharam; Chiao Yuen Lim; Hock Beng Chua; William Chong; Kim Khee Tan
Journal:  J Transplant       Date:  2021-04-20

Review 4.  Impact of National Economy and Policies on End-Stage Kidney Care in South Asia and Southeast Asia.

Authors:  Suceena Alexander; Sanjiv Jasuja; Maurizio Gallieni; Manisha Sahay; Devender S Rana; Vivekanand Jha; Shalini Verma; Raja Ramachandran; Vinant Bhargava; Gaurav Sagar; Anupam Bahl; Mamun Mostafi; Jayakrishnan K Pisharam; Sydney C W Tang; Chakko Jacob; Atma Gunawan; Goh B Leong; Khin T Thwin; Rajendra K Agrawal; Kriengsak Vareesangthip; Roberto Tanchanco; Lina H L Choong; Chula Herath; Chih C Lin; Nguyen T Cuong; Ha P Haian; Syed F Akhtar; Ali Alsahow; Mohan M Rajapurkar; Vijay Kher; Hemant Mehta; Anil K Bhalla; Umesh B Khanna; Deepak S Ray; Sonika Puri; Himanshu Jain; Aida Lydia; Tushar Vachharajani
Journal:  Int J Nephrol       Date:  2021-05-06

5.  Forecast of the incidence, prevalence and burden of end-stage renal disease in Nanjing, China to the Year 2025.

Authors:  Ling Sun; Lu-Xi Zou; Yu-Chen Han; Han-Ming Huang; Zhao-Ming Tan; Min Gao; Kun-Ling Ma; Hong Liu; Bi-Cheng Liu
Journal:  BMC Nephrol       Date:  2016-06-13       Impact factor: 2.388

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.